En desarrollo
Salud·hace 4 horasResumen IA
Lenacapavir: A Long-Acting HIV Prevention Drug Faces Access Challenges
Lenacapavir, an injectable HIV prevention drug requiring only two doses annually, offers a significant advantage over daily pills by improving adherence. Despite its potential, access remains limited due to high costs and exclusion from supply deals in several vulnerable regions, including parts of Latin America.
D
Deutsche Welle4 min de lectura
